We have new details about the LOM-BioQuest joint venture that was announced last week. The WSJ article about the JV emphasized the goals of supporting good science and expanding the two companies’ presence in the life sciences market.
I spoke to the Director of LOM BioQuest, Garrett Herman, and one of his associates yesterday about their vision for the joint venture. They also shared with me the letter they sent announcing the JV (pdf). Here are the highlights of the letter and our conversation:
- They are taking a broad view of “life sciences” and plan to have the JV be the intake point for all their new projects in the space.
- They want to take whatever approach will maximize the likelihood of good science succeeding and are willing to engage shareholders as well as management and boards.
- Although the JV does not have any current employees, it does have “the full attention of both firms.”
- For now, interested parties should contact the principals in the letter.
- The plan is to nurture a few dramatic successes that will allow them to have an in-house source (or a regular stable) of capital to lead future deals, and a revived Canadian investor ecosystem to syndicate to.
I look forward to seeing LOM-BioQuest’s private sector approach to combining operating and financial advisory services, which should complement analogous efforts at NRC-IRAP and MaRS Innovation…
1 response so far ↓
Monday Biotech Deal Review: October 25, 2009 « The Cross-Border Biotech Blog // October 26, 2009 at 9:53 am |
[...] week. Loewen, Ondaatje, McCutcheon Limited and Versant Partners Inc. are the co-lead agents (no LOM-BioQuest angle here?). The offering is priced at $0.48 per share, for gross proceeds to iCo of [...]